Stoke Therapeutics, INC 8-K filings

Stoke Therapeutics has announced the pricing of an upsized public offering expected to generate $125 million in gross proceeds.

Stoke Therapeutics reports significant and sustained reductions in seizure frequency and improvements in cognition and behavior in Dravet syndrome patients treated with STK-001.

Stoke Therapeutics announced its full year 2023 financial results, reporting a net loss of $104.7 million and a cash balance of $201.4 million, expected to fund operations through 2025.